254 related articles for article (PubMed ID: 26323429)
1. Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer.
Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
Curr Pharm Des; 2015; 21(29):4201-16. PubMed ID: 26323429
[TBL] [Abstract][Full Text] [Related]
2. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
Hamdy S; Haddadi A; Hung RW; Lavasanifar A
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
[TBL] [Abstract][Full Text] [Related]
3. Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy.
Kokate RA; Chaudhary P; Sun X; Thamake SI; Maji S; Chib R; Vishwanatha JK; Jones HP
Nanomedicine (Lond); 2016; 11(5):479-94. PubMed ID: 26892440
[TBL] [Abstract][Full Text] [Related]
4. PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.
Silva AL; Soema PC; Slütter B; Ossendorp F; Jiskoot W
Hum Vaccin Immunother; 2016 Apr; 12(4):1056-69. PubMed ID: 26752261
[TBL] [Abstract][Full Text] [Related]
5. PLGA/PLA micro- and nanoparticle formulations serve as antigen depots and induce elevated humoral responses after immunization of Atlantic salmon (Salmo salar L.).
Fredriksen BN; Grip J
Vaccine; 2012 Jan; 30(3):656-67. PubMed ID: 22100638
[TBL] [Abstract][Full Text] [Related]
6. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
7. Effects of Caryota mitis profilin-loaded PLGA nanoparticles in a murine model of allergic asthma.
Xiao X; Zeng X; Zhang X; Ma L; Liu X; Yu H; Mei L; Liu Z
Int J Nanomedicine; 2013; 8():4553-62. PubMed ID: 24376349
[TBL] [Abstract][Full Text] [Related]
8. Harnessing Dendritic Cells for Poly (D,L-lactide-
Koerner J; Horvath D; Groettrup M
Front Immunol; 2019; 10():707. PubMed ID: 31024545
[TBL] [Abstract][Full Text] [Related]
9. Hybrid poly(lactic-co-glycolic acid) nanoparticles: design and delivery prospectives.
Pandita D; Kumar S; Lather V
Drug Discov Today; 2015 Jan; 20(1):95-104. PubMed ID: 25277320
[TBL] [Abstract][Full Text] [Related]
10. Promising particle-based vaccines in cancer therapy.
Xiang SD; Scalzo-Inguanti K; Minigo G; Park A; Hardy CL; Plebanski M
Expert Rev Vaccines; 2008 Sep; 7(7):1103-19. PubMed ID: 18767957
[TBL] [Abstract][Full Text] [Related]
11. Aliphatic Polyester-Based Materials for Enhanced Cancer Immunotherapy.
Chin AL; Wang X; Tong R
Macromol Biosci; 2021 Jul; 21(7):e2100087. PubMed ID: 33909344
[TBL] [Abstract][Full Text] [Related]
12. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers.
Ungaro F; d'Angelo I; Coletta C; d'Emmanuele di Villa Bianca R; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F
J Control Release; 2012 Jan; 157(1):149-59. PubMed ID: 21864595
[TBL] [Abstract][Full Text] [Related]
13. Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens.
Singh SM; Alkie TN; Nagy É; Kulkarni RR; Hodgins DC; Sharif S
Vaccine; 2016 Sep; 34(40):4807-13. PubMed ID: 27543454
[TBL] [Abstract][Full Text] [Related]
14. Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.
Varypataki EM; Silva AL; Barnier-Quer C; Collin N; Ossendorp F; Jiskoot W
J Control Release; 2016 Mar; 226():98-106. PubMed ID: 26876760
[TBL] [Abstract][Full Text] [Related]
15. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity.
Keijzer C; Slütter B; van der Zee R; Jiskoot W; van Eden W; Broere F
PLoS One; 2011; 6(11):e26684. PubMed ID: 22073184
[TBL] [Abstract][Full Text] [Related]
16. PLGA based drug delivery systems: Promising carriers for wound healing activity.
Chereddy KK; Vandermeulen G; Préat V
Wound Repair Regen; 2016 Mar; 24(2):223-36. PubMed ID: 26749322
[TBL] [Abstract][Full Text] [Related]
17. Engineering PLGA nano-based systems through understanding the influence of nanoparticle properties and cell-penetrating peptides for cochlear drug delivery.
Cai H; Liang Z; Huang W; Wen L; Chen G
Int J Pharm; 2017 Oct; 532(1):55-65. PubMed ID: 28870763
[TBL] [Abstract][Full Text] [Related]
18. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.
Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A
Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320
[TBL] [Abstract][Full Text] [Related]
19. Biodegradable nanoparticles for drug and gene delivery to cells and tissue.
Panyam J; Labhasetwar V
Adv Drug Deliv Rev; 2003 Feb; 55(3):329-47. PubMed ID: 12628320
[TBL] [Abstract][Full Text] [Related]
20. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
